MSD Technology Transfer & ARV Licensing

Partnership objectives

  1. Expand Access to our antiretrovirals (ARVs).
  2. Reduce the cost of our antiretrovirals (ARVs) for people living in the world's poorest countries and those hardest hit by the epidemic.
  3. Address the impact of the disease in resource-limited settings.

MSD supports the UNITAID, Drugs for Neglected Diseases Initiative (DNDi) and the Medicines Patent Pool. MSD supports the UNITAID, Drugs for Neglected Diseases Initiative (DNDi) and the Medicines Patent Pool. Copyright MSD

Description of partnership activities and how they address needs and challenges

MSD* is committed to seeking additional ways to reduce the cost of our antiretrovirals (ARVs) for people living in the world's poorest countries and those hardest hit by the epidemic, including through working with external manufacturers and suppliers to achieve incremental efficiencies.

Summary of impact and forward looking information

MSD has established a low-cost supply chain with generic partners for the commercialization of ISENTRESS® (raltegravir) in all low income countries and all of sub-Saharan Africa. The implementation of this supply chain has allowed us to reduce the price of ISENTRESS to USD $1.85 per day (ex-MSD) price in these countries. MSD has granted multiple non-exclusive licenses to Indian generic manufacturersfor the manufacture and commercialization of raltegravir in 60 Low Income and sub-Saharan African countries. In addition, in February 2014, MSD and Cipla announced a strategic partnership to co-market raltegravir, 400mg tablet for the Indian market.

MSD also granted royalty-free licenses for efavirenz to six South African generic manufacturers.

Manufacturers to whom MSD has granted a royalty-free voluntary license for efavirenz include:

  • Emcure Pharmaceuticals S. Africa & Arrow Pharma S. Africa (joint license granted in 2011)
  • Sonke Pharmaceuticals—License granted in 2009
  • Aspen Pharmacare—License granted in 2008
  • Aurobindo Pharma—License granted in 2008
  • Cipla Medpro—License granted in 2008
  • Adcock Ingram Healthcare—License granted in 2007

MSD supports the UNITAID, Drugs for Neglected Diseases Initiative (DNDi) and the Medicines Patent Pool Foundation led multi-stakeholder initiative which seeks to increase access to pediatric HIV treatment through the development of improved or new pediatric formulations of HIV medicines.  In support of this initiative, in 2014, MSD has entered into negotiations with the Medicines Patent Pool regarding potential licenses on the pediatric formulations of raltegravir.

 

* MSD is known as Merck in the U.S. and Canada.

Videos

HIV/AIDS- Unwavering Committment

Partnership information

Company(ies) MSD

Partner(s) Adcock Ingram Healthcare, Aspen Pharmacare, Aurobindo Pharma, Cipla Medpro, Emcure Pharmaceuticals, Sonke Pharmaceuticals

Type of Partner(s) Generic Manufacturers

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Research & Development - Development of Treatments

Targeted Population(s) Patients in needs of treatment, People with low income

Region(s) South Asia, Sub-Saharan Africa

Number of Countries 2

Country(ies) India, South Africa

Start Date 2011

More information Merck Responsibility

Anticipated completion date Ongoing